Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Misses Expectations By $0.01 EPS

Syndax Pharmaceuticals (NASDAQ:SNDXGet Free Report) released its earnings results on Tuesday. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.01), Briefing.com reports. During the same period in the previous year, the company posted ($0.62) earnings per share.

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX opened at $23.88 on Thursday. Syndax Pharmaceuticals has a twelve month low of $11.22 and a twelve month high of $25.75. The stock has a fifty day simple moving average of $21.78 and a 200 day simple moving average of $17.91.

Institutional Trading of Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SNDX. Point72 Hong Kong Ltd acquired a new stake in Syndax Pharmaceuticals in the first quarter valued at $41,000. Royal Bank of Canada grew its holdings in Syndax Pharmaceuticals by 1,144.7% during the 3rd quarter. Royal Bank of Canada now owns 3,622 shares of the company’s stock worth $87,000 after acquiring an additional 3,331 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Syndax Pharmaceuticals by 12.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,441 shares of the company’s stock worth $114,000 after acquiring an additional 609 shares during the period. Sandia Investment Management LP acquired a new stake in Syndax Pharmaceuticals during the 4th quarter worth about $127,000. Finally, Tower Research Capital LLC TRC grew its holdings in Syndax Pharmaceuticals by 138.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,530 shares of the company’s stock worth $158,000 after acquiring an additional 4,374 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $41.00 target price on shares of Syndax Pharmaceuticals in a research note on Wednesday. StockNews.com upgraded Syndax Pharmaceuticals to a “sell” rating in a research note on Friday, January 19th. Mizuho started coverage on shares of Syndax Pharmaceuticals in a report on Friday, December 22nd. They set a “buy” rating and a $45.00 price target for the company. Finally, Scotiabank downgraded shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and lowered their price target for the stock from $36.00 to $23.00 in a report on Wednesday, January 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.75.

Read Our Latest Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Company Profile

(Get Free Report)

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).

Read More

Earnings History for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.